Uses of the drug Satigem

Satigem drug has the main ingredient is Gemcitabine, which is prepared in the form of lyophilized powder for intravenous infusion. Satigem is used in the treatment of certain cancers.

1 vial of Satigem 200 has the main ingredient Gemcitabine (as Gemcitabine hydrochloride) 200mg. Gemcitabine is toxic to many types of human tumor cells. The cytotoxic effect of the drug is specific at the G1/S boundary stage. The cytotoxic effect of Gemcitabine is mainly dependent on drug concentration and duration of administration. Besides, Gemcitabine has anti-tumor effect. Patients taking Gemcitabine may have clinical improvements or increased survival rates.
Indications for the use of Satigem:
Treatment of locally advanced or metastatic non-small cell lung cancer; Treatment of locally advanced or metastatic pancreatic cancer; Treatment of patients with pancreatic cancer resistant to 5-FU; Treatment of other cancers: metastatic breast cancer, ovarian cancer, cervical cancer, bladder cancer, prostate cancer, small cell lung cancer, kidney cancer,... Contraindications to the use of Satigem:
People who are sensitive or allergic to the drug's ingredients.

How to use: Mix the powder for intravenous infusion according to the standard ratio.
Dosage:
Non-small cell lung cancer: Gemcitabine dose is 1,000mg/m2, intravenous infusion over 30 minutes. Thereafter, this dose should be repeated once a week for 3 consecutive weeks, followed by a 1-week break. Thereafter, repeat the 4-week cycle as above. Dosage may be reduced based on the degree of toxicity occurring in the patient; Pancreatic cancer: Gemcitabine dose is 1,000mg/m2, intravenous infusion over 30 minutes. Thereafter, this dose should be repeated once a week for 7 consecutive weeks, followed by a 1-week break. Continue this dose once a week for 3 weeks, then stop for 1 week. Thereafter, repeat the 4-week cycle as above. Dosage may be reduced based on the degree of toxicity occurring in the patient; Elderly patients: Gemcitabine is well tolerated in patients over 65 years of age. There is currently no evidence that dose adjustment is necessary in the elderly, although age is a factor that may affect the clearance and half-life of Gemcitabine; Patients with hepatic and renal impairment: Gemcitabine should be used with caution because there are no studies on its use in this group of subjects; Children: There are no studies on the use of Gemcitabine in children. *Note:
Before each dose, the patient's white blood cell, granulocyte and platelet count should be monitored. When there are signs of toxicity on the blood, if necessary, the dose can be reduced or the drug discontinued; Periodic monitoring of liver and kidney function should be performed in patients receiving Gemcitabine (including testing for transaminases and serum creatinine); Gemcitabine was well tolerated by infusion, with only a few cases of infusion site reactions, with no reported risk of infusion site necrosis. Gemcitabine can be used for outpatients.

When using Satigem, patients may experience some side effects such as:
Blood: Anemia, thrombocytopenia, leukopenia, leukocytosis (due to bone marrow suppression); Liver: Abnormalities in liver transaminases, usually mild, non-progressive and rarely require discontinuation of the drug; Gastrointestinal: Nausea, vomiting; Allergic: Rash, itchy skin, vesicles, desquamation, ulcers, bronchospasm (rare); Other side effects: Flu-like symptoms such as fever, back pain, chills, headache, muscle pain, loss of appetite, weakness, cough, rhinitis, sweating, insomnia, edema (face edema, pulmonary edema) , ... or congestive heart failure, myocardial infarction, arrhythmia,... When experiencing side effects of Satigem, patients should immediately notify their doctor for advice and treatment of edema. unify.

Some notes patients need to remember before and while using Satigem:
Be careful when using Satigem in people with impaired liver and kidney function. It is best to periodically check liver and kidney function in patients; Satigem should not be used by people who are sensitive to the drug. Approximately 10% of patients experience shortness of breath within a few hours of using Gemcitabine. Dyspnea is usually mild, short-term, rarely requires dose limitation and usually resolves spontaneously without specific treatment; The safety and effectiveness of Satigem in pregnant and lactating women have not been established. Animal studies have shown reproductive toxicity (birth defects, effects on embryo and fetus development, pregnancy, perinatal and postnatal development). . Therefore, caution should be exercised when this drug is used in pregnant or lactating mothers; Use caution when using Satigem in children, drivers or operating machinery. When prescribed to use Satigem, patients need to inform their doctor about the drugs they are taking and their medical history. At the same time, patients should absolutely follow all instructions of the doctor to ensure optimal treatment effectiveness and limit the risk of unpredictable events.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.